Effect of adjuvant tranexamic acid on melasma – A Pilot Study

Variya Laothaworn, Premjit Juntongjin, Sompong Deananlarp, Junya Pattaraarchachai

Abstract


 

Keywords: melasma, tranexamic acid, laser

Objectives: To assess the additional effect of topical tranexamic acid on melasma

Methods: Ten melasma participants were included for an interventional split face trial for 8 weeks duration. Participants will receive 2 sessions of 1064 nm QS Nd: YAG laser plus topical tranexamic acid (group A) on one side of the face in one-month interval and 1064 nm QS Nd: YAG laser alone (group B) on the another side. Clinical responses were assessed by mexameter at baseline, 2nd, 4th and 8th week.

Results: Mean age of the participants were 44.6 years. All of them were female. The most common type of melasma was epidermal type, following by mixed type. At 8 weeks, melanin indices (combination group: 342.13 ± 24.17 – 334.13 ± 21.7; laser group: 345.06 ± 22.93 ­ 339.5 ± 22.32, p=0.452) and erythema indices (combination group: 365 ± 15.56 – 369.66 ± 18.87; laser group: 366.06 ± 13.8 ­ 348.26 ± 13.77, p=0.587) were not statistic significantly reduced from baseline. There was no difference reduction of melanin indices, erythema indices between the two groups.

Conclusion:Both topical tranexamic acid combining with low fluence QS Nd: YAG laser and laser treatment alone can reduce the pigmentation in melasma. According to the reduction of melanin indicies, in the combination treatment reveals the tendency in less pigmentation.

 


Full Text:

184-187

References


Grimes PE. Melasma. Etiologic and therapeutic considerations. Archives of dermatology. 1995;131(12):1453-7.

Sarkar R, Chugh S, Garg VK. Newer and upcoming therapies for melasma. Indian journal of dermatology, venereology and leprology. 2012;78(4):417-28.

Bandyopadhyay D. TOPICAL TREATMENT OF MELASMA. Indian Journal of Dermatology. 2009;54(4):303-9.

Kim MS, Bang SH, Kim JH, Shin HJ, Choi JH, Chang SE. Tranexamic Acid Diminishes Laser-Induced Melanogenesis. Annals of dermatology. 2015;27(3):250-6.

Sim JH, Park YL, Lee JS, Lee SY, Choi WB, Kim HJ, et al. Treatment of melasma by low-fluence 1064 nm Q-switched Nd:YAG laser. The Journal of dermatological treatment. 2014;25(3):212-7.

Shin JU, Park J, Oh SH, Lee JH. Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: a randomized, prospective trial. Dermatol Surg. 2013;39(3 Pt 1):435-42.

Na JI, Choi SY, Yang SH, Choi HR, Kang HY, Park KC. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. Journal of the European Academy of Dermatology and Venereology : JEADV. 2013;27(8):1035-9.

Wattanakrai P1 MR, Eimpunth S. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg 2010;36(1):76-87.

Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57(6):1005-32.

Tse TW, Hui E. Tranexamic acid: an important adjuvant in the treatment of melasma. Journal of cosmetic dermatology. 2013;12(1):57-66.


Refbacks

  • There are currently no refbacks.